CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.

Saved in:
Bibliographic Details
Title: CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.
Authors: Naito M; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA, USA., Hainz U, Burkhardt UE, Fu B, Ahove D, Stevenson KE, Rajasagi M, Zhu B, Alonso A, Witten E, Matsuoka K, Neuberg D, Duke-Cohan JS, Wu CJ, Freeman GJ
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2013 Feb; Vol. 62 (2), pp. 347-57. Date of Electronic Publication: 2012 Aug 25.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0851
DOI:10.1007/s00262-012-1331-4